Print Page  Close Window

Press Release

Quest Diagnostics Acquires PhenoPath, Broadening Access to Advanced Diagnostics
PhenoPath deepens Quest's presence in the Pacific Northwest while extending the company's capabilities in anatomic pathology and molecular oncology

SECAUCUS, N.J. and SEATTLE, Sept. 27, 2018 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has acquired PhenoPath, a national provider of specialized anatomic pathology (AP) and related services.

Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)

Based in Seattle, PhenoPath provides AP, molecular oncology and other services that complement and extend those of the company's Advanced Diagnostics portfolio of services. These include services, such as genetic sequencing and genomic tumor analysis, which require higher-order expertise and skill.

"Our acquisition of PhenoPath delivers on our accelerate growth strategy for advanced diagnostics," said Steve Rusckowski, Chairman, President and CEO, Quest Diagnostics. "PhenoPath has a strong record of innovation, and provides several capabilities that complement and extend our own, particularly in pathology and molecular oncology. It also deepens our presence in the Pacific Northwest."

The PhenoPath business will operate as part of AmeriPath, a wholly owned business of Quest Diagnostics. The leading provider of anatomic pathology services, AmeriPath provides high-end pathology services to many ambulatory health and surgery centers, imaging centers, clinics and physician offices, and has on-site community pathologists in more than 170 hospitals across the country.

AP and molecular oncology services are essential to diagnose many diseases, particularly cancer. In 2018, there will be an estimated 1,735,350 new cancer cases diagnosed in the United States, according to the American Cancer Society.

Additional terms of the transaction were not disclosed.

About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/quest-diagnostics-acquires-phenopath-broadening-access-to-advanced-diagnostics-300719454.html

SOURCE Quest Diagnostics

Wendy Bost, Quest Diagnostics (Media): 973-520-2800; Shawn Bevec, Quest Diagnostics (Investors): 973-520-2900